Profound Medical (PROF) Q4 2025: 43% Revenue Jump as Tulsa Pipeline Hits 110 Systems
Profound Medical posted a 43% revenue surge in Q4, with Tulsa Pro pipeline expansion and pivotal CAPTN trial data set to drive 2026 growth. Margin compression reflects international launch pricing, but management signals a path to profitability as recurring revenue ramps. Upcoming clinical and reimbursement catalysts position Profound for accelerated adoption and scale in the coming year.
Summary
- Pivotal Clinical Evidence Unveiled: CAPTN trial results to be presented imminently, supporting Tulsa Pro’s differentiated positioning.
- Pipeline and Install Base Expansion: Tulsa Pro pipeline grows to 110 systems, with targeted 42 new installs in 2026.
- Profitability Focus Intensifies: Management expects positive cash flow as recurring revenue and margin scale with adoption.
Performance Analysis
Profound Medical delivered a 43% year-over-year revenue increase in Q4 2025, driven by a blend of capital equipment sales and recurring revenue from Tulsa Pro procedures. Recurring revenue accounted for $2.3 million, while one-time capital sales contributed $3.7 million. Gross margin compressed to 67% from 71% in the prior year period, reflecting introductory pricing for international distributor launches in Saudi Arabia and Australia. Operating expenses remained stable at $11.4 million, but the net loss widened to $8.2 million, reflecting the company’s ongoing investment in commercial and R&D initiatives.
Cash balance at year-end stood at $59.7 million, with management emphasizing a trajectory toward cash flow positivity as the install base and recurring revenue scale. The Tulsa Pro installed base reached 78 sites at year-end, and the qualified sales pipeline expanded to 110 systems, supporting visibility into future growth. International distribution agreements contributed to the Q4 capital mix, but management reiterated that the long-term model is weighted toward recurring procedure revenue, targeting a 70%+ gross margin profile as scale is achieved.
- International Launches Dilute Margin: Initial distributor pricing impacted Q4 margin, but sets stage for broader global expansion.
- Install Base Momentum: 78 Tulsa Pro sites at year-end, with utilization expected to rise as reimbursement and clinical data improve.
- Recurring Revenue Remains Core: While capital sales dominated Q4 mix, management maintains focus on procedure-based recurring revenue as primary driver.
As Profound shifts from capital sales to recurring revenue, the company’s ability to scale procedure volumes per site and secure payer coverage will be key to sustainable margin expansion and eventual profitability.
Executive Commentary
"CAPTN completes the foundational pillars of clinical evidence validating TELSA as the new platform for prostate disease management... These advantages echo the same drivers that fueled early adoption of robotic surgery."
Dr. Arun Nanawat, Chief Executive Officer
"With just 200 Tulsa programs cases using existing MR installed base, assuming a conservative 50 Tulsa procedures per site per year and a $5,500 recurring revenue to profound per procedure, we would be at $55 million in procedural revenue... Altogether, this would put us around $85 million in annual revenue. With 70% plus gross margin already achieved, we would be profitable."
Tom Zamperino, Chief Commercial Officer
Strategic Positioning
1. Clinical Evidence as a Market Catalyst
CAPTN, the first multicenter randomized trial directly comparing Tulsa Pro to robotic prostatectomy, serves as a cornerstone for Profound’s clinical credibility. The imminent release of six-month safety and quality of life data—selected for a premier late-breaking session at EAU—positions Tulsa Pro as the only technology with “apples-to-apples” efficacy and QoL data versus surgery, an essential lever for payer coverage and urologist adoption.
2. Commercial Execution and Pipeline Visibility
The Tulsa Pro sales pipeline has grown to 110 qualified systems, with 42 new installs targeted for 2026. Profound’s commercial team now adopts a “hunter-farmer” model, with dedicated teams focused on both new sales and driving higher utilization at existing sites. Expansion into high-volume urology centers and targeted physician training are key to accelerating procedure ramp and recurring revenue growth.
3. Reimbursement and Payer Engagement
Reimbursement remains a central pillar, with Category 1 CPT codes secured for 2026 and Medicare payments set at a premium to robotic and focal therapies. Private payer coverage is tracking above 90% for reimbursement reversals, and management expects formal commercial coverage decisions in the second half of 2026. The new CMS policy for real-time MR-guided biopsy further strengthens the economic case for Tulsa Pro.
4. AI-Driven Workflow and BPH Module Expansion
Profound’s AI-based planning and workflow modules, including the new Volume Reduction module for BPH (benign prostatic hyperplasia), are reducing procedure time and enabling sites to treat both cancer and BPH patients efficiently. This expands the total addressable market by an estimated 400,000 patients annually and supports the creation of “full Tulsa days” for provider scheduling efficiency.
5. International Growth and Strategic Partnerships
Distribution agreements in Saudi Arabia and Australia/New Zealand have begun to contribute to system sales, with a cautious but growing international strategy focused on distributor-led expansion. Partnerships with OEMs like Siemens are advancing Tulsa Pro’s compatibility with new MR platforms, broadening the future install base and workflow integration.
Key Considerations
Profound’s Q4 performance underscores a transition from clinical validation to commercial scale, with several strategic levers in play for 2026.
Key Considerations:
- CAPTN Data Readout: Imminent presentation of pivotal trial results could accelerate both clinical adoption and payer reimbursement decisions.
- Utilization Ramp Critical: Average procedures per site remain below long-term targets; management expects material improvement in the second half of 2026, aided by new workflow modules and sales team structure.
- Recurring vs. Capital Mix: While capital sales will be elevated as the install base grows, management maintains that recurring revenue will ultimately dominate, supporting margin stability.
- International Market Dynamics: Early international sales required introductory pricing, but distributor model limits direct margin risk; future growth dependent on reimbursement and local adoption curves.
- Cash and Profitability Trajectory: Sequential reduction in cash burn signals operational leverage, with profitability modeled at $85 million in annual revenue, predicated on pipeline conversion and utilization gains.
Risks
Key risks include slower-than-expected utilization ramp at new sites, delays in private payer coverage, and potential pricing pressure as international markets scale. Gross margin volatility may persist in the near term due to product mix and introductory pricing. Clinical adoption is contingent on the strength and perception of upcoming CAPTN data, and any negative regulatory or reimbursement developments could materially impact growth trajectory.
Forward Outlook
For Q1 2026, Profound expects:
- Continued pipeline conversion, with Tulsa Pro installs pacing higher than Q4 exit rate
- CAPTN trial data to drive clinical and commercial momentum
For full-year 2026, management did not provide explicit revenue guidance but:
- Targets 42 new Tulsa Pro installs, with recurring revenue mix expected to rise in the second half
- Projects high double-digit to low triple-digit revenue growth, with profitability at $85 million annualized revenue
Management highlighted several factors that will influence 2026:
- Conversion of pipeline and pace of site utilization ramp
- Formal private payer coverage decisions in the second half
Takeaways
Profound Medical is entering a pivotal year, with CAPTN trial results and reimbursement milestones set to define its market trajectory. The balance between capital sales and recurring revenue will shape margin and cash flow dynamics as the business scales.
- Clinical Data as Growth Engine: CAPTN results are positioned to validate Tulsa Pro’s differentiated profile, supporting both adoption and payer coverage.
- Operational Leverage Emerging: Pipeline growth and install base expansion, combined with a focus on utilization, set the stage for improved cash flow and profitability.
- 2026 Watchpoints: Investors should monitor the pace of site utilization gains, the impact of BPH module adoption, and the conversion of the pipeline into recurring revenue streams.
Conclusion
Profound Medical’s Q4 marks a transition from clinical validation to commercial scale, with the CAPTN trial, reimbursement wins, and a growing pipeline setting the stage for accelerated growth and operational leverage. Execution on utilization ramp and payer coverage will be decisive for sustained margin expansion and eventual profitability.
Industry Read-Through
Profound’s progress underscores a broader shift in urology and interventional oncology toward MR-guided, AI-enabled, minimally invasive therapies. The focus on quality of life endpoints, payer economics, and workflow integration is likely to drive competitive responses from both surgical robotics and focal therapy incumbents. Reimbursement differentiation for real-time MR-guided procedures signals a potential inflection for other device makers seeking to move beyond legacy ultrasound-based platforms. The adoption and payer dynamics seen here may foreshadow similar patterns across other image-guided intervention markets.